Developed by Bernard Attali and Asher Peretz, MD, of the Sackler Faculty of Medicine, the medication, known as BL-7050, inhibits the transmission of pain signals throughout the body. In experiments measuring electrical activity of neurons, the drug has been shown to prevent the hyper-excitability of neurons, protecting against neuropathic pain and epileptic seizures.
Related Articles on Pain Management:
Study Sheds Doubt on Steroid Injections for Back Pain
Wisconsin to Have Statewide Drug Monitoring System
Most Patients Take Incorrect Dosages of Prescription Drugs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
